Peptide Library

Human study PLS-00095

Mitochondrial-Derived Peptides Are Down Regulated in Diabetes Subjects.

Cross-sectional study · 225 participants enrolled · not included in the assessments (other)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Mitochondrial-Derived Peptides Are Down Regulated in Diabetes Subjects.primary · Frontiers in endocrinology · 2019-05-31 · PMID 31214116 · DOI

Design and participants

Design
Cross-sectional study
Population
Adults classified as normal, pre-diabetes, type 2 diabetes with HbA1c below 7% (good control), or type 2 diabetes with HbA1c above 7% (poor control).
Conditions
type 2 diabetes, prediabetes
Planned enrollment (registry)
Not reported
Enrolled
225
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): The mitochondrial-derived peptides humanin and MOTS-c, like adiponectin, are lower in type 2 diabetes and correlate with HbA1c. The authors take this as further evidence that mitochondrial dysfunction contributes to glycemic dysregulation.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • inappropriate endpoint: The study measures endogenous serum MOTS-c levels and does not administer MOTS-c, so it cannot show any effect of the compound.
    • confounding: Cross-sectional group comparisons are used, and the abstract gives no clear adjustment for differences in age, BMI or medication.
    • abstract only: Only an abstract is available, and its results section is garbled, so no numerical values can be extracted.
    • other: Cross-sectional design measures endogenous levels and cannot show causal effects of giving MOTS-c; correlations may reflect confounding.
    • no control group: No MOTS-c intervention or placebo comparison. Groups were defined by glycemic status, not by treatment.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • arms: PMID 31214116, abstract (Subjects and Measurements, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • author_conclusion: PMID 31214116, abstract (Conclusion, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 31214116, abstract (Subjects and Measurements, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 31214116, abstract (Results section (garbled)) · extracted by AI (automated, not verified by a person) · abstract only
    • outcomes: PMID 31214116, abstract (Subjects and Measurements, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 31214116, abstract (Subjects and Measurements, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 31214116, abstract (Subjects and Measurements, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • results: PMID 31214116, abstract (Conclusion, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).